SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on treating inflammation through resolution therapy, today provides an update following it ...
Doctors initially though a man’s chronic headaches were signs of a deadly brain cancer, but the reality was much grosser.
In autoimmune disorders, immune cells targeting "self" proteins are mistakenly activated, resulting in abnormal expansion and ...
Last week, MLB proposed an inflammatory set of CBA reforms that, among many other limitations, would kill the type of ...
Ramiz Alakbarov, Deputy Special Coordinator for the Middle East Peace Process and UN Resident and Humanitarian Coordinator, ...
Viridian Therapeutics receives US FDA approval for Lumvoa for the treatment of thyroid eye disease: Waltham, Massachusetts Tuesday, June 30, 2026, 13:00 Hrs [IST] Viridian Therape ...
Adults who received sonelokimab for moderate to severe hidradenitis suppurativa experienced consistent disease improvement ...
Viridian Therapeutics has scored an FDA approval for Lumvoa to treat thyroid eye disease (TED), triggering competition with ...
About XWRAP® XWRAP is a placental-derived wound covering intended for the management of chronic wounds. Applied Biologics continues to evaluate XWRAP through prospective clinical research programs ...
MedPage Today on MSN
New Drug Approved for Thyroid Eye Disease
Veligrotug labeling shows data for both the active and chronic forms of TED ...
The U.S. Food and Drug Administration has approved Viridian Therapeutics' drug to treat patients with thyroid eye disease, the company said on Friday.
A prespecified secondary analysis of the S-LiTE trial found that regular exercise reduced carotid artery wall thickness and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results